Lecanemab

Lecanemab and what this means for the future treatment of Alzheimer’s disease

The Phase III NILEAD trial: nilotinib as a novel treatment for AD

Updates in pharmacological treatment of Alzheimer’s disease: lecanemab, donanemab and gantenerumab

Important developments in dementia: biomarkers & clinical trials

Targeting β-amyloid and tau in Alzheimer’s disease

Comparing binding characteristics to Aβ of lecanemab, aducanumab & gantenerumab

Lecanemab path to approval

The development of lecanemab & rationale behind its unique binding profile

The potential of lecanemab for the treatment of early Alzheimer’s disease

Lecanemab for the treatment of early Alzheimer’s disease: the story so far

Aducanumab: what’s the latest?

Lecanemab: Phase II open-label extension results

Major ongoing clinical trials in AD: aducanumab, donanemab & lecanemab

Phase III AHEAD 3-45 trial of lecanemab for preclinical Alzheimer’s disease

Clinical trial for BAN2401 in early Alzheimer’s: combining ADCOMS and Bayesian statistics

Outstanding amyloid response to BAN2401: slowing progression in early Alzheimer’s